RenovoRx, Inc. (RNXT) is a Biotechnology company in the Healthcare sector, currently trading at $1.03. It has a SharesGrow Score of 56/100, indicating a above average investment profile with 3 out of 7 criteria passed.
Valuation: RNXT trades at a trailing Price-to-Earnings (P/E) of -3.1 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.09.
Financials: revenue is $1M, +2511.6%/yr average growth. Net income is $11M (loss), growing at -5.9%/yr. Net profit margin is -994.5% (negative). Gross margin is 70.9% (-29.1 pp trend).
Balance sheet: total debt is $107,000 against $5M equity (Debt-to-Equity (D/E) ratio 0.02, conservative). Current ratio is 4.02 (strong liquidity). Debt-to-assets is 1.3%. Total assets: $8M.
Analyst outlook: 4 / 5 analysts rate RNXT as buy (80%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 100/100 (Pass), Moat 35/100 (Fail), Future 90/100 (Pass), Income 10/100 (Fail).
